Cargando…
Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
BACKGROUND: Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363688/ https://www.ncbi.nlm.nih.gov/pubmed/25781618 http://dx.doi.org/10.1371/journal.pone.0118174 |
_version_ | 1782361958079528960 |
---|---|
author | Riccio, Eleonora Sabbatini, Massimo Bruzzese, Dario Capuano, Ivana Migliaccio, Silvia Andreucci, Michele Pisani, Antonio |
author_facet | Riccio, Eleonora Sabbatini, Massimo Bruzzese, Dario Capuano, Ivana Migliaccio, Silvia Andreucci, Michele Pisani, Antonio |
author_sort | Riccio, Eleonora |
collection | PubMed |
description | BACKGROUND: Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no data, however, about a direct effect of paricalcitol on hemoglobin (Hb) levels. Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD). METHODS: In this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL) were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary endpoint was to evaluate the effects of the two treatments on Hb levels; the modifications in 24hr-proteinuria (UProt) were also evaluated. RESULTS: A significant Group x Time interaction effect was observed in the longitudinal analysis of Hb levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL (95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation markers remained in the normal range in both groups throughout the study. CONCLUSIONS: Short-term exposure to paricalcitol results in an independent increase in Hb levels, which occurred with no modification of iron balance, inflammatory markers, and PTH plasma concentrations, and was associated with a decrease in UProt. TRIAL REGISTRATION: ClinicalTrials.gov NCT01768351 |
format | Online Article Text |
id | pubmed-4363688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43636882015-03-23 Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial Riccio, Eleonora Sabbatini, Massimo Bruzzese, Dario Capuano, Ivana Migliaccio, Silvia Andreucci, Michele Pisani, Antonio PLoS One Research Article BACKGROUND: Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no data, however, about a direct effect of paricalcitol on hemoglobin (Hb) levels. Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD). METHODS: In this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL) were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary endpoint was to evaluate the effects of the two treatments on Hb levels; the modifications in 24hr-proteinuria (UProt) were also evaluated. RESULTS: A significant Group x Time interaction effect was observed in the longitudinal analysis of Hb levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL (95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation markers remained in the normal range in both groups throughout the study. CONCLUSIONS: Short-term exposure to paricalcitol results in an independent increase in Hb levels, which occurred with no modification of iron balance, inflammatory markers, and PTH plasma concentrations, and was associated with a decrease in UProt. TRIAL REGISTRATION: ClinicalTrials.gov NCT01768351 Public Library of Science 2015-03-17 /pmc/articles/PMC4363688/ /pubmed/25781618 http://dx.doi.org/10.1371/journal.pone.0118174 Text en © 2015 Riccio et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Riccio, Eleonora Sabbatini, Massimo Bruzzese, Dario Capuano, Ivana Migliaccio, Silvia Andreucci, Michele Pisani, Antonio Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title | Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title_full | Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title_fullStr | Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title_full_unstemmed | Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title_short | Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial |
title_sort | effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363688/ https://www.ncbi.nlm.nih.gov/pubmed/25781618 http://dx.doi.org/10.1371/journal.pone.0118174 |
work_keys_str_mv | AT riccioeleonora effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT sabbatinimassimo effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT bruzzesedario effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT capuanoivana effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT migliacciosilvia effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT andreuccimichele effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial AT pisaniantonio effectofparicalcitolvscalcitriolonhemoglobinlevelsinchronickidneydiseasepatientsarandomizedtrial |